Michael Pfreundschuh

发表

Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma.

M. Pfreundschuh, U. Rebmann, G. Jakse, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.

H Tesch, D Hasenclever, M Sieber, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

T. Brümmendorf, K. Spiekermann, M. Pfreundschuh, 2017, Leukemia.

Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib

H. Einsele, J. Hasford, K. Spiekermann, 2014, Leukemia.

Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT).

W. Stevens, M. Pfreundschuh, C. Sebban, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment

N. Schmitz, H. Heimpel, H. Döhner, 2015, Leukemia.

Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study.

A. Ho, R. Pettengell, J. Walewski, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Six versus eight cycles of biweekly CHOP-14 with or without R in elderly patients (pts) with aggressive CD20+ B-cell lymphomas: Seven-year FU of the RICOVER-60 trial of the DSHNHL.

M. Ziepert, N. Schmitz, M. Pfreundschuh, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis.

G. Salles, B. Coiffier, M. Ghielmini, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone.

R. Greil, R. Müller, N. Willich, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

N. Schmitz, M. Pfreundschuh, M. Loeffler, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group.

V. Diehl, N. Schmitz, J. Franklin, 1998, Blood.

Randomized intergroup trial of first line treatment for patients <=60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab -early stopping after the first interim analysis.

M. Pfreundschuh, M. Loeffler, P. Zinzani, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.